Engelhardt M, Rump J A, Hellerich U, Mertelsmann R, Lindemann A
Medizinische Klinik I, University of Freiburg, Germany.
Ann Hematol. 1995 Apr;70(4):227-30. doi: 10.1007/BF01700380.
Interleukin-2 (IL-2) has been licensed for the treatment of renal cell carcinoma and is currently being evaluated as a therapeutic agent in hematological malignancies. It is associated with a variety of side effects due to induction of a nonspecific inflammatory response. However, phenomena of autoimmunity have also been reported. Here we describe a patient with secondary acute myeloid leukemia who developed a leukocytoclastic vasculitis during long-term post-remission treatment with very low doses of IL-2.
白细胞介素-2（IL-2）已被批准用于治疗肾细胞癌，目前正作为一种治疗药物在血液系统恶性肿瘤中进行评估。由于诱导非特异性炎症反应，它会引发多种副作用。然而，也有自身免疫现象的报道。在此，我们描述一名继发性急性髓系白血病患者，该患者在缓解期后长期接受极低剂量IL-2治疗期间发生了白细胞破碎性血管炎。
